• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

替奈普酶溶栓治疗时代前、大脑中动脉闭塞患者的溶栓后结局。

Stroke outcomes of Japanese patients with major cerebral artery occlusion in the post-alteplase, pre-MERCI era.

机构信息

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

出版信息

J Stroke Cerebrovasc Dis. 2013 Aug;22(6):805-10. doi: 10.1016/j.jstrokecerebrovasdis.2012.05.009. Epub 2012 Jun 19.

DOI:10.1016/j.jstrokecerebrovasdis.2012.05.009
PMID:22721823
Abstract

This study examined outcomes of patients with acute ischemic stroke (AIS) with major cerebral artery occlusion after the approval of intravenous recombinant tissue-type plasminogen activator (IV rt-PA) but before approval of the MERCI retriever. We retrospectively enrolled 1170 consecutive patients with AIS and major cerebral artery occlusion (496 women; mean age, 73.9 ± 12.3 years) who were admitted within 24 hours after the onset of symptoms to 12 Japanese stroke centers between October 2005 and June 2009. Cardioembolism was a leading cause of AIS in this group (68.2%). The occlusion sites of the major cerebral arteries included the common carotid artery and internal carotid artery (ICA; 29.6%), middle cerebral artery (52.2%), and basilar artery (7.6%). Recanalization therapy (RT) was performed in 32.0% of patients (IV rt-PA, 20.0%; neuroendovascular therapy, 9.4%; combined, 2.5%). Symptomatic intracerebral hemorrhage within 36 hours with a ≥ 1-point increase in the National Institutes of Health Stroke Scale score occurred in 5.3% of the patients. At 3 months (or at hospital discharge), 29.3% of the patients had a favorable outcome (based on a modified Rankin scale score of 0-2), 23.8% were bedridden, and 15.6% died. After multivariate adjustment, RT was positively associated with a favorable outcome and negatively associated with death, whereas age, baseline National Institutes of Health Stroke Scale score, and ICA occlusion were negatively associated with a favorable outcome and positively associated with death. One-third of the patients with AIS and major cerebral artery occlusion were treated with RT, which was independently associated with favorable outcomes and death. However, 40% of the patients became bedridden or died during the post-alteplase, pre-MERCI era in Japan.

摘要

这项研究调查了在批准静脉注射重组组织型纤溶酶原激活剂(IV rt-PA)但在批准 MERCI 取栓器之前,患有急性缺血性脑卒中(AIS)伴大脑主要动脉闭塞的患者的结局。我们回顾性纳入了 2005 年 10 月至 2009 年 6 月期间,12 家日本卒中中心收治的 1170 例发病 24 小时内的 AIS 伴大脑主要动脉闭塞患者(496 例女性,平均年龄 73.9 ± 12.3 岁)。心源性栓塞是该组 AIS 的主要病因(68.2%)。主要大脑动脉闭塞部位包括颈总动脉和颈内动脉(29.6%)、大脑中动脉(52.2%)和基底动脉(7.6%)。32.0%的患者接受了血管再通治疗(RT)(IV rt-PA,20.0%;神经血管内治疗,9.4%;联合治疗,2.5%)。36 小时内出现症状性颅内出血,NIHSS 评分增加≥1 分的患者占 5.3%。3 个月时(或出院时),29.3%的患者预后良好(改良 Rankin 量表评分 0-2),23.8%卧床不起,15.6%死亡。多变量调整后,RT 与良好结局呈正相关,与死亡呈负相关,而年龄、基线 NIHSS 评分和颈内动脉闭塞与良好结局呈负相关,与死亡呈正相关。三分之一的 AIS 伴大脑主要动脉闭塞患者接受了 RT 治疗,与良好结局和死亡独立相关。然而,在日本,接受阿替普酶治疗后、MERCI 取栓器治疗前的这一时期,40%的患者卧床不起或死亡。

相似文献

1
Stroke outcomes of Japanese patients with major cerebral artery occlusion in the post-alteplase, pre-MERCI era.替奈普酶溶栓治疗时代前、大脑中动脉闭塞患者的溶栓后结局。
J Stroke Cerebrovasc Dis. 2013 Aug;22(6):805-10. doi: 10.1016/j.jstrokecerebrovasdis.2012.05.009. Epub 2012 Jun 19.
2
Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.静脉注射 rt-PA 治疗卒中患者后 24 小时内的早期神经功能恶化:卒中急性管理伴紧急风险因素评估和 rt-PA 改善登记研究。
Cerebrovasc Dis. 2012;34(2):140-6. doi: 10.1159/000339759. Epub 2012 Aug 1.
3
Wake-up stroke within 3 hours of symptom awareness: imaging and clinical features compared to standard recombinant tissue plasminogen activator treated stroke.症状出现后 3 小时内发生的唤醒性卒中:与标准重组组织型纤溶酶原激活剂治疗的卒中的影像学和临床特征比较。
J Stroke Cerebrovasc Dis. 2013 Aug;22(6):703-8. doi: 10.1016/j.jstrokecerebrovasdis.2011.10.003. Epub 2011 Nov 30.
4
Factors associated with early recanalization failure following intravenous rt-PA therapy for ischemic stroke.与静脉注射 rt-PA 治疗缺血性脑卒中后早期再通失败相关的因素。
Cerebrovasc Dis. 2013;36(4):299-305. doi: 10.1159/000355054. Epub 2013 Oct 16.
5
Intravenous alteplase at 0.6 mg/kg for acute stroke patients with basilar artery occlusion: the stroke acute management with urgent risk factor assessment and improvement (SAMURAI) Recombinant tissue plasminogen activator registry.急性脑梗死患者基底动脉闭塞静脉溶栓:急性卒中治疗中紧急风险因素评估和改善(SAMURAI)重组组织型纤溶酶原激活物溶栓登记研究。
J Stroke Cerebrovasc Dis. 2013 Oct;22(7):1098-106. doi: 10.1016/j.jstrokecerebrovasdis.2012.08.013. Epub 2012 Oct 10.
6
Efficacy of endovascular treatment for acute cerebral large-vessel occlusion: analysis of nationwide prospective registry.急性大脑大血管闭塞血管内治疗的疗效:全国前瞻性注册分析。
J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1183-90. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.014. Epub 2014 Jan 11.
7
Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.日本 4 家医院组织中的组织型纤溶酶原激活物溶栓治疗急性缺血性脑卒中。
J Stroke Cerebrovasc Dis. 2013 Apr;22(3):190-6. doi: 10.1016/j.jstrokecerebrovasdis.2011.07.016. Epub 2011 Oct 2.
8
Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke?肥胖患者接受急性缺血性脑卒中静脉溶栓治疗是否颅内出血和死亡率降低?
J Stroke Cerebrovasc Dis. 2013 May;22(4):545-9. doi: 10.1016/j.jstrokecerebrovasdis.2013.01.022. Epub 2013 Feb 28.
9
Significance of magnetic resonance angiography-diffusion weighted imaging mismatch in hyperacute cerebral infarction.磁共振血管造影-弥散加权成像不匹配对超急性脑梗死的意义。
J Stroke Cerebrovasc Dis. 2012 Feb;21(2):108-13. doi: 10.1016/j.jstrokecerebrovasdis.2010.03.019. Epub 2010 Sep 19.
10
Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neuro-unit.日本神经科单位使用组织型纤溶酶原激活剂对缺血性中风进行系统溶栓的上市后1年经验。
Clin Neurol Neurosurg. 2007 Sep;109(7):567-70. doi: 10.1016/j.clineuro.2007.05.002. Epub 2007 Jun 15.

引用本文的文献

1
Guidelines for Mechanical Thrombectomy in Japan, the Fourth Edition, March 2020: A Guideline from the Japan Stroke Society, the Japan Neurosurgical Society, and the Japanese Society for Neuroendovascular Therapy.《日本机械取栓指南(2020年3月第四版):来自日本卒中学会、日本神经外科学会和日本神经血管内治疗学会的指南》
Neurol Med Chir (Tokyo). 2021 Mar 15;61(3):163-192. doi: 10.2176/nmc.nmc.st.2020-0357. Epub 2021 Feb 11.
2
Predictors of functional outcome in patients with stroke thrombolysis in a tertiary hospital in Malaysia.马来西亚一家三甲医院中接受溶栓治疗的脑卒中患者的功能结局预测因素。
Singapore Med J. 2019 May;60(5):236-240. doi: 10.11622/smedj.2018150. Epub 2018 Nov 29.
3
Model-based assessment of the benefits and risks of recombinant tissue plasminogen activator treatment in acute ischaemic stroke.
基于模型的急性缺血性脑卒中重组组织型纤溶酶原激活剂治疗的获益与风险评估。
Br J Clin Pharmacol. 2018 Nov;84(11):2586-2599. doi: 10.1111/bcp.13715. Epub 2018 Aug 21.
4
The efficiency analysis of thrombolytic rt-PA combined with intravascular interventional therapy in patients with acute basilar artery occlusion.急性基底动脉闭塞患者溶栓用rt-PA联合血管内介入治疗的疗效分析
Int J Biol Sci. 2017 Jan 1;13(1):57-64. doi: 10.7150/ijbs.16029. eCollection 2017.